Абстракт

Objectives: To analyze the difference between polynucleotide alone therapy and polynucleotide + botulinum toxin combination therapy, and the recent trend of the entire polynucleotide therapy (including both group) for skin rejuvenation in efficacy, safety, and patient’s satisfaction. Introduction: Polynucleotide therapy for skin rejuvenation which our group adopted in July 2018 for improving the skin quality of especially the lower eyelid has been more popular overtime. We performed 55,410 cases in total from July 2018 to the end of January 2023. Materials / method: We investigated the number of treatments of polynucleotide alone group and polynucleotide + botulinum toxin group, and number of adverse events and patient’s satisfaction from our database and medical record from 2018 to the end of January 2023. The aim of this study is to analyze the difference of both group and the recent trend of the entire polynucleotide therapy (including both group). Results: Since last year, when a mixture product of polynucleotide and botulinum toxin, the number of cases of polynucleotide + botulinum toxin combination therapy (n = 12,890; Feb 2022 to Jan 2023) has been higher than the number of cases using polynucleotide alone therapy (n = 6,738), which is one of recent new trends on polynucleotide therapy. The entire number of polynucleotide therapy was 19,628, which has been increasing year by year since 2018 (n = 1,975 in 2018, n = 5,078 in 2019, n = 4,536 in 2,020, n = 6,463 in 2021, and n = 17,730 in 2022). Conclusion: We can see from the above history of the number of the entire polynucleotide therapy that the total number of polynucleotide therapy cases increased dramatically in 2022 when polynucleotide + botulinum toxin combination therapy was adopted. We report the more detailed results of this study and show some findings from the results.